Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2026-02-10

Study results available
· View outcomes & findings →

Summary

This randomized, single blinded, clinical trial aims to investigate the efficacy of a multimodal pain control regimen for shoulder arthroplasty. Patients who receive a multimodal pain control regimen alone (study group) will be compared to patients who receive a multimodal pain control regimen plus a standard prescription of an opioid containing medication (comparison group). The primary outcome is average daily Numerical Rating Scale (NRS) pain score in the first 10 days after surgery. We hypothesize that there will be no significant difference in the primary outcome between the two groups.

Conditions

  • Shoulder Arthropathy
  • Shoulder Pain

Interventions

DRUG

Celecoxib

preoperative pain medication given to all patients

DRUG

Pregabalin

preoperative and discharge pain medication given to all patients

DRUG

Tramadol

preoperative pain medication given to all patients

DRUG

Dexamethasone

Intraoperative and discharge pain medication given to all patients

DRUG

Acetaminophen

Intraoperative and discharge pain medication given to all patients

DRUG

Ropivicaine

Intraoperative pain medication given to all patients

DRUG

Epinephrine

Intraoperative pain medication given to all patients

DRUG

Ketorolac

Intraoperative pain medication given to all patients

DRUG

Tizanidine

Discharge pain medication given to all patients

DRUG

Magnesium

Discharge pain medication given to all patients

DRUG

Ibuprofen

Discharge pain medication given to all patients

DRUG

Oxycodone Hydrochloride 5 Mg

Only given to active comparator group

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Stephanie J Muh, MD · Henry Ford Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-25
Primary Completion
2024-12-11
Completion
2026-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05488847 on ClinicalTrials.gov